secwatch.observer — SEC 8-K summary
======================================

Issuer:     Veradermics, Inc (MANE)
CIK:        0001827635
Form:       8-K
Filed at:   2026-05-12T12:32:47+00:00
Accession:  0001827635-26-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veradermics Q1 net loss $27.2M, positive Phase 2/3 results for VDPHL01 hair loss drug
--------------------------------------------------------------------------------

- Net loss $27.2M for Q1 2026 vs $12.4M Q1 2025; R&D $20.9M, G&A $8.9M.
- Positive Phase 2/3 topline results for VDPHL01 in male pattern hair loss; 12-month data H2 2026.
- Enrollment completed in Study '304' (Phase 3, male PHL); topline data H2 2026. Study '306' (female PHL) enrolling.
- Raised ~$766.8M gross from IPO and follow-on; cash $390.8M at Mar 31, 2026, expected to fund into 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827635/000182763526000016/0001827635-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827635/000182763526000016/mane-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001827635-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer